This is a summary of the European public assessment report (EPAR) for Tolucombi. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Tolucombi. For practical information about using Tolucombi, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Tolucombi fixed-dose combination (80 mg telmisartan/25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on Tolucombi 80 mg/12.5 mg (80 mg telmisartan/12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.
Therapeutic Area (MeSH)
ATC Code
C09DA07
ATC Item
telmisartan and diuretics
Pharmacotherapeutic Group
telmisartan and diuretics
Active Substance (Summary)
INN / Common Names
EMA Name
Tolucombi
Medicine Name
Tolucombi
Aliases
N/ANo risk management plan link.
